New advances in the treatment of hepatitis B;Neue ansätze in der hepatitis B-therapie

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 21, 2004, Pages 1203-1208

  Sagir, A ^a   Avci, A ^a   Erhardt, A ^a   Lorke J ^a   Heintges, T ^a   Haussinger D ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 126433; ADEFOVIR; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; INTERFERON; LAMIVUDINE; PEGINTERFERON; TENOFOVIR; UNCLASSIFIED DRUG; 2 AMINOPURINE; 2'-FLUORO-5-METHYLARABINOSYLURACIL; ADEFOVIR DIPIVOXIL; ADENINE; ALPHA INTERFERON; ALPHA2A INTERFERON; DEOXYCYTIDINE; DEXELVUCITABINE; DRUG DERIVATIVE; GUANINE; MACROGOL DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; PHOSPHONIC ACID DERIVATIVE; PRODRUG; TENOFOVIR DISOPROXIL; URACIL ARABINOSIDE; ZALCITABINE;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION; LIVER CELL CARCINOMA; PATIENT; PROGNOSIS; REVIEW; SEROCONVERSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRAL GENETICS; DRUG CONTRAINDICATION; LIVER TUMOR; MORTALITY;

2-AMINOPURINE; ADENINE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LAMIVUDINE; LIVER NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; PRODRUGS; PROGNOSIS; ZALCITABINE;

EID: 2942683439     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-824872     Document Type: Review

References (42)

1. Afdhal NH, O'Brien CB, Oshana SC. Potent anti-HBV activity of ACH-126,443 correlated with 14-day pharmacokinetics and safety: Predictions for activity against YMDD mutant strains. Hapatology 2002; 36: 372A
2. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297
3. Bochet M, Tubiana R, Benhamou R et al. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients co-infected with H1V/HBV. 9th Conference on Retroviruses and Opportunistic Infections, 2002: 675-M
4. Buti M, Esteban R. Adefovir dipivoxil. Drugs Today 2003; 39: 127-135
5. Bryant ML, Bridges E, Placidi L et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 229-235
6. Chang TT, Hadziyannis S, Cianciara J et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002; 36: 300A
7. Cooksley WGE, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305
8. de Franchis R, Meucci G, Vecchi M et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191-194
9. de Man RA, Marcellin P et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32: 413-417
10. Deres K, Schroder CH, Paessens A et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893-896
11. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263
12. Erhardt A, Reineke U, Blondin D et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716-725
13. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 1998; 45: 1206-1213(Suppl 3
14. Gerken G, Gomes J, Lampertico P, Colombo M et al. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 1998; 74: 155-165
15. Gish R, Leung N, Wang C, Sacks S et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. Hepatology 2002; 36: 372A
16. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficiacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. Gastroenterol Hepatol 2001; 16: A60
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807
18. Hadziyannis SJ, Tassopoulus N, Heathcote EJ et al. 96 weeks of Adefovir dipivoxil in HbeAg negative CHB: significant virological, biochemical and histological improvement. EASL, 2003
19. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13 (Suppl 1); S47-S49
20. Klein C, Bock CT, Wedemeyer H et al. Inhibition of hepatitis B virus replikation in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125: 9-18
21. Korba BE, Schinazi RF, Cote P, Tennant BC, Gerin JL. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 2000; 44: 1757-1760
22. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
23. Lai CL, Myers MW, Pow MD, Lee YM, Yuen MF, Lim SG. Safe and potent suppresion of hepatitis B virus (HBV) with L-deoxythymidine (LDT): results of a dose escalation trial. Hepatology 2001; 34: 321A
24. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis HBe antigen serocoversion rates: Results after 3 years of therapy. Hepatology 2001; 33: 1527
25. Leung N, Gish RG, Wang C et al. A randomized, double-blind comparison of 3 doses of emtricitabine (FTC) in patients with chronic hepatitis B (CHB) given 48 weeks of treatment (FTCB-102). Hepatology 2001; 34: 349A
26. Liaw YD, Tai C, Chu T, Chen T. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1998; 8: 493-496
27. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975
28. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816
29. Marcellin P, Lau GKK, Mommeja-Marin H et al. A phase I/II dose escalating trialevaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV. EASL, 2003
30. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990; 8 (Suppl); S18-20
31. Nelson M, Portsmouth SD, Stebbing J et al. Tenofovir in the treatment of individuals co-infected with HIV-1 and Hepatitis B. International AIDS Conference Barcelona, 2002: B7302
32. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427
33. Perrillo RP, Wright T, Rakela J et al. Multicenter united states canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-432
34. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194
35. Sagir A, Heintges T, Erhardt A, Kirschberg O, Häussinger D. Daily interferon alfa 2a dosing improves response rates in patients with chronic hepatitis B dramatically. Hepatology 2002; 36: 624A
36. Schalm SW. Clinical implications of lamivudine resistance by HBV. Lancet 1997; 349: 3-4
37. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-568
38. Sung JJY, Lai JK, Zeuzem S et al. A randomised double-blind phase II study of Laminvudine (LAM) compared to Lamivudine plus Adefovir Dipivoxil (ADV) for treatment naive patients with chronic Hepatitis B (CHB): week 52 analysis. J Hepatol 2003; 38: 25-26
39. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-896
40. Thomas HC, Karayiannis P, Brook G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. J Hepatol 1991; 13 (Suppl 1); 4-7
41. Villeneuve JP, Condray LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatits B. Hepatology 2000; 31: 207-210
42. Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003; 36: 1516-1522